search
Back to results

Influence of Exercise, Weight Loss, and Exercise Plus Weight Loss on Sleep Apnea

Primary Purpose

Obstructive Sleep Apnea, Overweight

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Exercise
Weight Loss
Exercise + Weight Loss
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obstructive Sleep Apnea focused on measuring exercise, weight loss, sleep apnea

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Veteran
  • 18-65 years of age
  • Moderate-severity OSA [[Apnea-hypopnea index (AHI) 15 at screening]
  • Overweight/obese
  • Physically inactive
  • BMI 28
  • Sedentary lifestyle (planned activity for purpose of health < 2 days/week)
  • Stable weight Not engaged in weight loss study or program
  • Stable medications Medications for thyroid, cholesterol, blood pressure, and other conditions at same dose for 2 months
  • Capable of signing consent and willing to provide informed consent and accept randomization assignment

Exclusion Criteria:

  • Current OSA treatment Current use of continuous positive airway pressure (PAP), dental devices, etc. for OSA treatment. Past PAP or oral appliances are not exclusions if discontinued 2 months before study
  • Significant disease: known or signs/symptoms of cardiovascular, metabolic, or pulmonary disease
  • Uncontrolled hypertension: Blood pressure > 159/99 mmHg
  • Unable to exercise: musculoskeletal, orthopedic, neuromuscular, or other conditions that do not allow exercise or where exercise is contraindicated
  • Any accident attributable to sleepiness in previous 3 years
  • Current pregnancy/planning to become pregnant
  • Clinically judged unsuitable as evaluated by supervising medical physician

Sites / Locations

  • Phoenix VA Health Care System, Phoenix, AZ

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Exercise

Weight Loss

Exercise + Weight Loss

Arm Description

16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week

16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement

Combined components of the exercise and weight loss treatments

Outcomes

Primary Outcome Measures

Apnea-hypopnea Index (AHI)
Common criterion for obstructive sleep apnea: number of apnea and hypopnea episodes per hour of sleep. Baseline-end - positive value indicates a reduction.

Secondary Outcome Measures

Functional Outcomes of Sleepiness Questionnaire (FOSQ)
Measures impairments in functioning associated with sleepiness. Baseline minus end of study value. Positive value indicates improvement; negative value indicates worsening. Minimum score on scale: 0 Maximum score: 120
Snoring Severity Scale
Questionnaire that measures severity of snoring with a questionnaire. A positive value indicates improvement; a negative value indicates worsening. Minimum score: 0 Maximum score: 9
Pittsburgh Sleep Quality Index (PSQI)
Commonly used metric of sleep quality. Baseline minus end of study. Positive value indicates improvement. Minimum score: 0 Maximum score: 21
Blood Pressure
Blood pressure
Body Weight
Fasting body weight. Weight change (kg) beginning to end of study (positive valuate = decrease)
Percent Body Fat Assessed With Dual-energy X-reay Absorptiometry (DEXA)
Percent body fat assessed with DEXA. Change in percent body fat - positive value represents a decrease.
C-reactive Protein (CRP)
Measure of inflammation

Full Information

First Posted
February 17, 2016
Last Updated
April 9, 2021
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT02721251
Brief Title
Influence of Exercise, Weight Loss, and Exercise Plus Weight Loss on Sleep Apnea
Official Title
Influence of Exercise, Weight Loss, and Exercise Plus Weight Loss on Sleep Apnea
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Terminated
Why Stopped
Behind enrollment targets
Study Start Date
April 1, 2016 (Actual)
Primary Completion Date
September 30, 2019 (Actual)
Study Completion Date
September 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Obstructive sleep apnea (OSA) is highly prevalent among Veterans, and is associated with significant mortality and multiple morbidities. Available treatments have had limited effectiveness in treating OSA and alleviating associated morbidity. The investigators' previous research found a reduction in OSA severity of approximately 25% following modest exercise training. That this effect occurred independent of weight loss raises the exciting possibility that exercise combined with weight loss could reduce OSA by at least 50% and have unique health benefits for OSA patients. Following screening and baseline assessments, 90 overweight Veterans ages 18-60 years with OSA will be randomized to one of three 16-week treatments: (1) exercise training; (2) 10 % weight loss; and 3) exercise + weight loss. Changes in OSA and related morbidity will be compared between treatments.
Detailed Description
Rationale: Approximately 15-20% of adults have obstructive sleep apnea (OSA), and evidence indicates that the prevalence of OSA is perhaps twice as high among Veterans. OSA has been clearly linked to increased mortality and multiple morbidities, and undoubtedly contributes to the high prevalence of health problems among Veterans. Current treatments for OSA are not well tolerated, often have limited efficacy, and often do not result in improvements in health. The investigators' recent research demonstrated that 12 weeks of moderate exercise training elicited a reduction of OSA of ~25%, as well as significant improvement in mood, fatigue, quality of life, and cardiovascular health. Interestingly, as with other health benefits of exercise, the investigators' research is consistent with other research showing that exercise can reduce OSA independent of changes in body weight. These studies raise the exciting possibility that exercise training combined with modest weight loss could elicit a chronic reduction in OSA of 50% or more. Objectives: The investigators' Objective is to compare the effects of 16 weeks of exercise training alone, weight loss alone, and exercise + weight loss on OSA severity and associated morbidity. Methods: Following extensive screening and baseline assessment, N=90 overweight/obese Veterans (ages 18-60 years) with mild to severe OSA will be randomized to one of three 16-week treatments. (1) Exercise Alone (n=30) will involve training 4 days per week under supervision of a clinical exercise physiologist. It will include aerobic exercise (treadmill, cycling, elliptical) that will gradually increase to 30-45 min on 4 days/wk, as well as resistance exercise (15 min) on 2 days/week. (2) Weight Loss Alone (n=30) will involve a structured meal plan (including some meal replacement with shakes or bars), and weekly counseling designed to elicit a reduction in body weight of 10%. (3) Exercise + Weight Loss (n=30) will involve the same exercise and weight loss interventions as in the other treatments. Outside of the interventions, participants will be asked to maintain their usual exercise and diet habits, as verified, respectively, with actigraphic recording and a 24-hr food recall. Before and after the treatments, participants will undergo 5 days/nights of home-based actigraphic and diary-assessed sleep, and one night of laboratory polysomnographic recording of sleep, including OSA severity. Comorbidity measures will include pre- to post-treatment changes in blood pressure, glucose, insulin, lipids, hemoglobin a1c, body weight/composition, and inflammation (e.g., CRP, IL-6). Also measured will be monthly changes in self-reports of sleep quality, functional outcomes of sleepiness (FOSQ), and snoring symptoms. A 3-month follow-up will include home assessment of OSA, as well as sleep quality, FOSQ, and snoring. Mediation analysis will explore whether improvements in OSA are mediated by changes in percent of deep sleep, body weight, trunk body fat percent, trunk total mass, respiratory muscle strength, and upper airway obstruction assessed in the laboratory. Implications for Future Research. Demonstration of a reduction of OSA by 50% would result in extensive subsequent studies. These would likely include studies of dose-response effects; comparisons of different modes of exercise; studies of the feasibility of telemedicine approaches to the interventions; comparative efficacy studies vs. PAP; further mechanistic studies, for example, of upper airway collapsibility and composition (e.g, via MRI); and studies of other positive health outcomes, such as extensive heart imaging.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea, Overweight
Keywords
exercise, weight loss, sleep apnea

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercise
Arm Type
Experimental
Arm Description
16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
Arm Title
Weight Loss
Arm Type
Experimental
Arm Description
16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
Arm Title
Exercise + Weight Loss
Arm Type
Experimental
Arm Description
Combined components of the exercise and weight loss treatments
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Intervention Description
16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
Intervention Type
Behavioral
Intervention Name(s)
Weight Loss
Intervention Description
16 week. the goal is 10% weight loss.
Intervention Type
Behavioral
Intervention Name(s)
Exercise + Weight Loss
Intervention Description
Combined exercise and weight loss components of the other arms
Primary Outcome Measure Information:
Title
Apnea-hypopnea Index (AHI)
Description
Common criterion for obstructive sleep apnea: number of apnea and hypopnea episodes per hour of sleep. Baseline-end - positive value indicates a reduction.
Time Frame
Change from baseline to the end of the study (16-week intervention)
Secondary Outcome Measure Information:
Title
Functional Outcomes of Sleepiness Questionnaire (FOSQ)
Description
Measures impairments in functioning associated with sleepiness. Baseline minus end of study value. Positive value indicates improvement; negative value indicates worsening. Minimum score on scale: 0 Maximum score: 120
Time Frame
Change from baseline to the end of the study (16-week intervention)
Title
Snoring Severity Scale
Description
Questionnaire that measures severity of snoring with a questionnaire. A positive value indicates improvement; a negative value indicates worsening. Minimum score: 0 Maximum score: 9
Time Frame
Change from baseline to the end of the study (16-week intervention)
Title
Pittsburgh Sleep Quality Index (PSQI)
Description
Commonly used metric of sleep quality. Baseline minus end of study. Positive value indicates improvement. Minimum score: 0 Maximum score: 21
Time Frame
Change from baseline to the end of the study (16-week intervention)
Title
Blood Pressure
Description
Blood pressure
Time Frame
Change from baseline to the end of the study (16-week intervention)
Title
Body Weight
Description
Fasting body weight. Weight change (kg) beginning to end of study (positive valuate = decrease)
Time Frame
Change from baseline to the end of the study (16-week intervention)
Title
Percent Body Fat Assessed With Dual-energy X-reay Absorptiometry (DEXA)
Description
Percent body fat assessed with DEXA. Change in percent body fat - positive value represents a decrease.
Time Frame
Change from baseline to the end of the study (16-week intervention)
Title
C-reactive Protein (CRP)
Description
Measure of inflammation
Time Frame
Change from baseline to the end of the study (16-week intervention)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Veteran 18-65 years of age Moderate-severity OSA [[Apnea-hypopnea index (AHI) 15 at screening] Overweight/obese Physically inactive BMI 28 Sedentary lifestyle (planned activity for purpose of health < 2 days/week) Stable weight Not engaged in weight loss study or program Stable medications Medications for thyroid, cholesterol, blood pressure, and other conditions at same dose for 2 months Capable of signing consent and willing to provide informed consent and accept randomization assignment Exclusion Criteria: Current OSA treatment Current use of continuous positive airway pressure (PAP), dental devices, etc. for OSA treatment. Past PAP or oral appliances are not exclusions if discontinued 2 months before study Significant disease: known or signs/symptoms of cardiovascular, metabolic, or pulmonary disease Uncontrolled hypertension: Blood pressure > 159/99 mmHg Unable to exercise: musculoskeletal, orthopedic, neuromuscular, or other conditions that do not allow exercise or where exercise is contraindicated Any accident attributable to sleepiness in previous 3 years Current pregnancy/planning to become pregnant Clinically judged unsuitable as evaluated by supervising medical physician
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shawn D. Youngstedt, PhD
Organizational Affiliation
Phoenix VA Health Care System, Phoenix, AZ
Official's Role
Principal Investigator
Facility Information:
Facility Name
Phoenix VA Health Care System, Phoenix, AZ
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85012
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Influence of Exercise, Weight Loss, and Exercise Plus Weight Loss on Sleep Apnea

We'll reach out to this number within 24 hrs